4D Molecular Therapeutics, Inc.
FDMT
$9.48
-$0.39-3.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.90% | -45.79% | -78.49% | -68.75% | -59.53% |
| Total Depreciation and Amortization | 13.72% | 15.46% | 16.35% | 15.75% | 16.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -9.51% | -1.08% | 2.11% | -3.08% | 2.01% |
| Change in Net Operating Assets | 1,049.35% | -106.12% | 809.19% | -294.50% | -14.76% |
| Cash from Operations | 18.95% | -61.85% | -95.40% | -99.10% | -77.57% |
| Capital Expenditure | 85.84% | 54.08% | -70.09% | -50.14% | -36.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 69.05% | 114.22% | 117.94% | 98.13% | -352.05% |
| Cash from Investing | 69.26% | 113.58% | 116.73% | 96.21% | -361.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -66.51% | -99.54% | -99.42% | -96.04% | 115.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -66.51% | -99.54% | -99.42% | -96.04% | 115.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.70% | -57.69% | -136.83% | -172.11% | -150.71% |